Skip to content

LSD research published in 2025

Page 4 of 6: studies 61 to 80 of 118, newest first. Back to the LSD overview

Studies

Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium.

Journal of Psychopharmacology May 28, 2025 Yana Vella, Kateřina Syrová, Aneta Petrušková et al. 1 citation

Recent evidence suggests that psychedelics can induce rapid and long-lasting antidepressant effects. The generally acknowledged explanation for these traits is the phenomenon of neuroplasticity, although the exact underlying molecular mechanisms remain unclear. This study investigates the effects of psilocin, lysergic acid diethylamide (LSD) and N,N-dimethyltryptamine (DMT) on synaptogenesis...

Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study.

Clinical Pharmacology & Therapeutics May 26, 2025 Denis Arikci, Friederike Holze, Lorenz Mueller et al. 6 citations

Lysergic acid diethylamide (LSD) is currently being investigated as a potential treatment for psychiatric and neurological disorders. Different LSD formulations (base or tartrate, oral or intravenous) are being used. Unclear is whether LSD base and tartrate pharmacokinetics are equivalent. Additionally, LSD's absolute oral bioavailability is unknown. Therefore, we tested the bioequivalence of...

DOI: 10.1002/cpt.3726 (opens in new tab) Full text (opens in new tab) Psychedelics Pharmacology Drug absorption Medical research +1

Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists.

British Journal of Pharmacology May 23, 2025 Trevor Sharp, Aurelija Ippolito 8 citations

Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s. However, these drugs are now experiencing a renaissance in the field of psychiatry based on increasing evidence that...

Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice.

Psychopharmacology May 17, 2025 Shelby A. McGriff, Jacquelin C Hecker, Alexander D. Maitland et al. 12 citations

The head twitch response (HTR) is a spontaneously occurring behavior in mice that is increased in frequency by serotonergic psychedelics. The mouse HTR is often used as a proxy for psychedelic-like drug effects, but limited information is available about sex differences in HTRs evoked by various classes of psychedelics (i.e., phenethylamines, lysergamides, tryptamines). To examine potential sex...

DOI: 10.1007/s00213-025-06795-x (opens in new tab) Full text (opens in new tab) 5-ht2a Head twitch response Mice Psychedelics hallucinogens +6

Pathway engineering for the biosynthesis of psychedelics

Current Opinion in Biotechnology May 15, 2025 Zachary N. Abrahms, Abhishek K. Sen, J. Andrew Jones 2 citations

Naturally occurring psychoactive compounds have been used for cultural and ethnomedical purposes for centuries. Several more such molecules continue to be chemically synthesized, exhibiting a wide range of potency, therapeutic, and hallucinogenic effects. Promising clinical data and a renewed interest in understanding the cellular mechanisms of action have inspired synthetic biology efforts to...

Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review

Journal of Psychopharmacology May 12, 2025 Clémentine Estric, Thomas Duron, Sarah Kabani et al. 10 citations

Psychedelics offer promising outcomes in psychiatry. However, the preparation of participants (set) and the environmental conditions of taking a psychedelic (setting) are not standardized. We describe the set and setting for therapeutic use of psychedelic drugs in people with psychiatric disorders. In this systematic review, articles were identified in the PubMed and Web of Science databases...

Exploring the Role of Psychedelics in Modulating Ego and Treating Neuropsychiatric Disorders.

ACS Chemical Neuroscience May 7, 2025 Hongshuang Wang, Xiaohui Wang 5 citations

This viewpoint explores the therapeutic potential of psychedelics in treating neuropsychiatric disorders, particularly through the modulation of brain entropy and the experience of ego dissolution. Psychedelics disrupt rigid neural patterns, facilitating enhanced connectivity and fostering profound emotional breakthroughs that may alleviate symptoms of disorders like depression, anxiety, PTSD,...

Are the LSD-analogs lisuride and ergotamine examples of non-hallucinogenic serotonin 5-HT2A receptor agonists?

Journal of Psychopharmacology May 5, 2025 Jan Kehler, Morten Skøtt Thomsen Lindskov 3 citations

The recent resurgence of classical psychedelic compounds, specifically 5-HT2A receptor agonists, as potential therapeutics has led to numerous initiatives aimed at better understanding the mechanisms underlying their effects. Psychedelic compounds are commonly known as hallucinogens. One of the major outstanding questions in the field is whether altered states of consciousness-the...

Clinical treatment of cluster headache with the serotonergic indoleamine psychedelics psilocybin and LSD and with ketamine: A case series

Cephalalgia Reports May 1, 2025 Jonathan A. Leighton, Chieh Grace Lau, Aisha Savdo et al. 2 citations

Background Cluster headache is an excruciating condition for which standard treatments are usually insufficient. Evidence has accumulated that serotonergic psychedelic indoleamines including psilocybin and LSD can be effective in preventing attacks. Methods In this case series, nine patients with episodic and chronic cluster headache that didn’t respond to conventional treatments were treated...

Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.

European journal of anaesthesiology May 1, 2025 Mansi Dave, Ron Shore, Tracy Cupido et al.

Psychedelic drugs, known for their perception-altering properties, are gaining popularity in the treatment of mental health and pain disorders. As exploratory studies demonstrate clinical efficacy with few adverse events, it is expected that more patients will ingest psychedelic drugs. For therapeutic reasons, as with any drug, anaesthesiologists must be aware of its physiological effects and...

DOI: 10.1097/eja.0000000000002138 (opens in new tab) Full text (opens in new tab) Drug interactions Psychedelic medicine Anesthesia safety Surgical protocols +1

The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis.

Neuroscience & Biobehavioral Reviews May 1, 2025 Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al. 36 citations

Psychedelic-assisted therapies have demonstrated promising results in treating mental disorders, with results suggesting that the subjective intensity and quality of psychedelic experiences plays a significant role in mediating therapeutic effects. However, the strength of this association across diagnoses and treatment settings remains underexplored. We searched MEDLINE, Embase, and PsycINFO...

Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.

Drug safety May 1, 2025 Ahmed Al-Imam, Riccardo Lora, Marek A Motyka et al. 1 citation

Psychedelics are gaining attention for their therapeutic potential in modern and personalized medicine. Online forums such as Erowid provide valuable user insights, but analyses of these experiences using natural language processing (NLP) remain scarce. This study aims to utilize NLP, including sentiment and lexicon analysis, to examine user-generated experience reports on psilocybin-containing...

DOI: 10.1007/s40264-025-01530-z (opens in new tab) Full text (opens in new tab) Consciousness research Altered states Psychedelics Drug effects

Innovation and inequity in psychedelic research at the Mayo Clinic.

History of Psychiatry April 28, 2025 Casimir Klim, Bryan VanDreese, Terence Meyerhoefer et al.

This paper provides an overview of psychedelic research at the Mayo Clinic in the 1950s and 1960s, focusing on methods, objectives, findings, and ethical practices. We highlight instances where researchers prioritized scientific progress over the autonomy, safety, and equitable treatment of research subjects, and discuss this history in the context of ongoing challenges with informed consent...

Exploring Factors Affecting Psychological Flexibility After Psychedelic Experiences.

Journal of Psychoactive Drugs April 25, 2025 Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al.

Neurobiological effects and psychological models propose that psychedelics may promote psychological flexibility, suggesting a transdiagnostic effect by disrupting maladaptive patterns. The objective of this study was therefore to investigate the determinants of psychological flexibility change following a psychedelic use. This retrospective online survey included French individuals who had...

DOI: 10.1080/02791072.2025.2495937 (opens in new tab) Full text (opens in new tab) Psilocybin Psychological flexibility Psychedelics LSD Hallucinogens +5

Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress

Psychedelic Medicine April 22, 2025 Sean M. Viña 6 citations

Objective: Prior research has found an association between psychedelic use and reduced stigma attached to mental illness. However, whether psychedelics alleviate stigma-related distress remains unclear. Since stigma impacts different groups uniquely, any moderating effect of psychedelics on stigma-related distress is likely to vary across subpopulations. This study addresses two main questions:...

Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure.

Journal of Psychopharmacology April 21, 2025 Einat Karp Barnir, Zohar Rubinstein, Rany Abend et al. 7 citations

Emerging evidence indicates the therapeutic potential of psychedelic compounds for post-traumatic stress, yet the mechanisms mediating their effects remain unclear. Delineating the effect of psychedelics on traumatic memory formation could shed light on target therapeutic mechanisms. Here, we report on 343 adult survivors of a single, large-scale terrorist attack taking place during a festival...

Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers.

Journal of Psychopharmacology April 18, 2025 James D Morse, Soo Hee Jeong, Robin J Murphy et al. 3 citations

Microdosing is the practice of taking psychedelic drugs at doses that produce no or minimal perceptible subjective or behavioural effects. This study investigated the pharmacokinetics and pharmacodynamics of microdosed lysergic acid diethylamide (LSD). This was a Phase 1 double-blind placebo-controlled parallel-groups trial with 80 healthy male volunteers (four withdrawals due to anxiety)....

DOI: 10.1177/02698811251330747 (opens in new tab) Full text (opens in new tab) LSD Pharmacodynamics Psychedelics hallucinogens Microdosing sub-perceptual dosing +5

Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential

Proceedings of the National Academy of Sciences April 14, 2025 Jeremy R Tuck, Lee E. Dunlap, Yara A Khatib et al. 32 citations

Decreased dendritic spine density in the cortex is a key pathological feature of neuropsychiatric diseases including depression, addiction, and schizophrenia (SCZ). Psychedelics possess a remarkable ability to promote cortical neuron growth and increase spine density; however, these compounds are contraindicated for patients with SCZ or a family history of psychosis. Here, we report the...

DOI: 10.1073/pnas.2416106122 (opens in new tab) LSD Neuroplasticity Neuropsychiatric disease Nonhallucinogenic +9

Identification of two lysergic acid diethylamide analogs, 1-(3-(trimethylsilyl) propionyl) lysergic acid diethylamide (1S-LSD) and 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD), in paper sheet products distributed on the internet.

Forensic Toxicology April 3, 2025 Rie Tanaka, Maiko Kawamura, Michiho Ito et al. 3 citations

Recently, numerous lysergic acid diethylamide (LSD) analogs have emerged as designer drugs globally. These compounds are mainly distributed as sheet products. In this study, two new LSD analogs were identified from sheet products. The structures of the compounds were determined by gas chromatography-mass spectrometry, liquid chromatography-photodiode array-mass spectrometry, liquid...

Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry April 2, 2025 Viktoriia Kurkova, Olga Winkler, Andrew J. Greenshaw et al.

This scoping review addresses the need to comprehensively explore the potential of psychedelic-assisted psychotherapy (PAP) to facilitate recovery from moral injury. Moral injury (MI), characterized by profound psychological distress arising from morally challenging experiences, has garnered increased attention as a complex mental health concern with significant functional sequelae, especially...